TooNiceStocks Initiates Coverage on BioSante Pharmaceuticals, Inc. Looming February 14th, 2012 FDA Decision with Elevated Interest

BioSante Pharmaceuticals is a development stage biotech company focusing on drugs for sexual health and oncology. TooNiceStocks research discovered the recent collapse in the company’s stock on December 14, 2011 from the day’s high of 2.60 to a low of 0.38 in after hours trading, have left many investors asking, "so what’s next for BioSante?" Since then, BioSante has slowly recovered somewhat, the stock is still trading at a much-reduced range of $.50, a substantial discount of roughly $52 million market cap compared to about $286 million before the news. However with one drug approved and another facing a regulatory decision in the form of a PDUFA on February 14th, 2012, smallcap investors are already gambling.

(PRWeb January 13, 2012)

Read the full story at

Morning After Pill – Politics Slaps Science Down, And Wins

Even though America has, by far, the highest rates of unwanted and unplanned teenage pregnancies in the developed world, and the FDA wanted to make the Morning-After-Pill, otherwise known as Plan B One-Step, available as an over-the-counter (OTC) drug to all females of reproductive age, HHS Secretary Kathleen Sebelius slapped them down and said “No”…

Bisphosphonates – New Labeling Data On Long-term Usage Recommended By FDA Advisory Panel

Bisphosphonates, medications for the treatment and prevention of osteoporosis and other bone conditions, should have additional data on their labels on treatment duration, an FDA Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee (the Panel) recommended. However, the panel did not go as far as advising that specific time limits be included…

FDA Warns Against Placing A Mesh Through The Vagina To Repair Pelvic Organ Prolapse

The surgical placement of mesh via the vagina to repair pelvic organ prolapse may be riskier for the patient compared to other surgical procedures, the FDA (Food and Drug Administration) has warned doctors. The FDA adds that other options carry less risk than this transvaginal surgical procedure…

Dr. Pinkerton on Menopause and health management

In the last part of my interview, Dr. JoAnn V. Pinkerton discusses menopause and healthcare management for healthier postmenopausal years! (PRISTIQ for hot flash treatment pending FDA approval)

Next Page »